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Abstract Canakinumab is a high-affinity human monoclonal anti-interleukin-1b (IL-1b) antibody of the IgG1/k
isotype designed to bind and neutralize the activity of human IL-1b, a pro-inflammatory cytokine. Cana-
kinumab is currently being investigated on the premise that it would exert anti-inflammatory effects on a
broad spectrum of diseases, driven by IL-1b. This paper focuses on the analysis of the pharmacokinetic and
pharmacodynamic data from the canakinumab clinical development programme, describing results from
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the recently approved indication for the treatment of cryopyrin-associated periodic syndromes (CAPS)
under the trade name ILARIS, as well as diseases such as rheumatoid arthritis, asthma and psoriasis.
Canakinumab displays pharmacokinetic properties typical of an IgG1 antibody. In a CAPS patient
weighing 70 kg, slow serum clearance (0.174L/day) was observed with a low total volume of distribution at
steady state (6.0 L), resulting in a long elimination half-life of 26 days. The subcutaneous absolute
bioavailability was high (70%). Canakinumab displays linear pharmacokinetics, with a dose-proportional
increase in exposure and no evidence of accelerated clearance or time-dependent changes in pharmaco-
kinetics following repeated administration was observed. The pharmacokinetics of canakinumab in various
diseases (e.g. CAPS, rheumatoid arthritis, psoriasis or asthma) are comparable to those in healthy indi-
viduals. No sex- or age-related pharmacokinetic differences were observed after correction for body weight.
An increase in total IL-1b was observed in both healthy subjects and all patient populations following
canakinumab dosing, reflecting the ability of canakinumab to bind circulating IL-1b. The kinetics of total
IL-1b along with the pharmacokinetics of canakinumab were characterized by a population-based
pharmacokinetic-binding model, where the apparent in vivo dissociation constant, signifying binding affin-
ity of canakinumab to circulating IL-1b, was estimated at 1.07– 0.173 nmol/L in CAPS patients.
During development of canakinumab a cell line change was introduced. Pharmacokinetic character-
ization was performed in both animals and humans to assure that this manufacturing change did not affect
the pharmacokinetic/pharmacodynamic properties of canakinumab.
1. Introduction
Canakinumab is a high-affinity human anti-interleukin (IL)-1b
monoclonal antibody of the IgG1/k isotype, which functionally
neutralizes the bioactivity of this pro-inflammatory cytokine.
Its specificity is confined to human and marmoset IL-1b, and
does not cross-react with cynomolgus or rhesus monkey IL-1b.
IL-1b is produced mainly by mononuclear phagocytes in res-
ponse to injury and infection and plays a dominant role in the
pathobiology of autoinflammatory syndromes, such as cryo-
pyrin-associated periodic syndromes (CAPS),[1-3] systemic
juvenile idiopathic arthritis,[4] adult and juvenile rheumatoid
arthritis,[5] and gouty arthritis.[6] IL-1b is also indicated to play
a key role in other chronic inflammatory conditions such as
asthma,[7] chronic obstructive pulmonary disease,[8] psoriasis[9]
and type 2 diabetes mellitus.[10]
The clinical effectiveness of canakinumab was demonstrated
in CAPS patients in a randomized phase III clinical trial.[11]
CAPS is a group of rare, inherited, autoinflammatory condi-
tions caused by single point mutations in the NALP3/CIAS1
gene resulting in increased production of IL-1b.[2] CAPS covers
a spectrum of individual disorders that could be classified into
the following subtypes: (i) familial cold autoinflammatory syn-
drome, also known as familial cold urticaria; (ii) Muckle-Wells
syndrome; and (iii) neonatal onset multisystem inflammatory
disease, also known as chronic, infantile, neurologic, cuta-
neous, articular (CINCA) syndrome. Canakinumab treatment
was associated with a decrease of IL-1b-induced downstream
mediators including IL-1b itself, IL-1b pathway-related genes,
acute phase proteins such as serum amyloid A (SAA) and
C-reactive protein (CRP), resulting in rapid remission of symp-
toms in most patients. Canakinumab is approved in more than
40 countries for the treatment of CAPS under the trade name
ILARIS.
This paper summarizes the clinical pharmacokinetic and phar-
macodynamic data of canakinumab in healthy individuals as well
as in several patient populations (rheumatoid arthritis [RA], pso-
riasis and asthma), with special emphasis on CAPS patients. The
data for this paper are based on six clinical trials with canakinumab
(pharmacokinetics/pharmacodynamics), as detailed in table I.
2. Pharmacology
IL-1 is an inflammatory cytokine produced by a variety of
cell types, particularly mononuclear phagocytes, in response to
injury, infection and cellular activation. The biological activity
of IL-1 is encoded by two distinct genes, IL-1a and IL-1b, with
IL-1b being the main secreted form in vivo. The equilibrium
dissociation constant for canakinumab binding to human
IL-1b, determined by surface plasmon resonance, is 60pmol/L
(unpublished data from the authors). Canakinumab inhibits the
IL-6 production in human primary fibroblasts induced by human
IL-1b with a concentration producing 50% inhibition (IC50) of
about 40pmol/L (unpublished data from the authors).
In vivo, following administration, the binding of canakinumab
to circulating IL-1b results in the formation of a canakinumab-
IL-1b complex. This complex, due to its larger molecular size, is
expected to be eliminated at a much slower rate than the free
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IL-1b, thus resulting in the elevation of total (free plus bound)
IL-1b levels. Total IL-1b concentrations can therefore be used
as a surrogate pharmacodynamic marker of ‘drug activity’ (i.e.
binding of IL-1b by the antibody), as it is easily detected fol-
lowing canakinumab administration. The ability of canakinu-
mab to bind and capture circulating IL-1bhasbeen validated in all
clinical studies, in patients andhealthy volunteers (figures 1 and2).
Vugmeyster et al.[17] reported examples of anti-cytokine proteins
that function as ‘cytokine traps’ by binding the free circulating
cytokine. The free circulating cytokines, which would have
otherwise been eliminated rapidly, are cleared slowly, resulting in
increased total circulating drug-bound cytokine.
3. Product Description
Canakinumab is a human anti-IL-1b monoclonal IgG1/k
antibody, expressed in Sp2/0 mouse myeloma cells, which
was derived from a genetically engineered mouse carrying the
human immunoglobulin repertoire. The cell line for canakin-
umab production was switched from NS0 to Sp2/0 during
canakinumab development. NS0 is a mouse myeloma line ori-
ginally derived from a plasmacytoma of a female Balb/c mouse.[18]
Sp2/0-Ag14 was isolated as a re-clone of Sp2/HL-Ag, which
was derived in several steps from Sp2/HLGK, a hybrid between
a BALB/c spleen cell with anti-sheep red blood cell activity and
myeloma cell line X63-Ag8,[19] itself derived from a plasmacy-
toma of a female BALB/c mouse. Except for the phase III trial
in CAPS patients,[11] the drug material from the NS0 cell line
was used in all the clinical trials presented in the current review.
The relative molecular mass of canakinumab based on the
amino acid composition without post-translational glycosylation,
but including N-terminal pyroglutamate formation and the
C-terminal lysine residues at the heavy chains, is 145.157kDa.
The product is supplied as a sterile, lyophilized powder for
solution for injection in glass vials that contain 150mg of
canakinumab. Canakinumab can be administered as an intra-
venous infusion over 120 minutes or as a subcutaneous injec-
tion. The approved starting dose of canakinumab for CAPS
patients with body weight >40 kg is 150mg, and with body
weight ‡15kg and £40kg is 2mg/kg, administered every 8 weeks
as a single dose via subcutaneous injection.[20,21]
3.1 Analytical Methods
3.1.1 Pharmacokinetic Assay
Canakinumab was analysed in human serum using a specific
competitive ELISA method with a lower limit of quantifica-
tion (LLQ) of 100 ng/mL. This method was based on a purified
Table I. Summary of canakinumab clinical study designs
Study Objective Dosing scheme
CACZ885B2101[12] Safety, tolerability and pharmacokinetics in healthy
subjects and safety, tolerability and pharmacokinetics/
pharmacodynamics in mild asthmatic patients
Three dose levels: 1, 3 and 10mg/kg, administered as a 2-hour IV infusion
on day 1 and day 15
CACZ885A1101
(NCT00421226)[13]
Safety, tolerability and pharmacokinetics/
pharmacodynamics in Japanese healthy volunteers
Cohorts 1–3: 1mg/kg, 3mg/kg and 600mgadministered as a 2-hour IV infusion
Cohorts 4–5: 150 and 300mg administered SC
Cohort 6: 600mg IV infusion followed 2 hours later by a 300mg SC dose
CACZ885A2101
(NCT00619905)[14]
Safety, tolerability and pharmacokinetics/
pharmacodynamics in patients with active RA taking
methotrexate
Four dose levels: 0.3, 1.0, 3.0 and 10.0mg/kg, administered on day 1 and




Safety, tolerability, immunogenicity and pharmacokinetics/
pharmacodynamics in psoriasis patients
Three treatment groups: 150mg SC SD, 150mg SC MD once a week for
4 weeks, and placebo. Dosing on days 1, 8, 15 and 22
CACZ885A2102
(NCT00487708)[16]
Clinical efficacy, safety and pharmacokinetics/
pharmacodynamics in patients with NALP3 mutations
(CAPS patients)
Stage 1: 10mg/kg 2-hour IV infusion; additional 1mg/kg IV infusion at
relapse
Stage 2: 150mg SC (or 2mg/kg for paediatric subjects) upon each relapse
CACZ885D2304
(NCT00465985)[11]
Efficacy, safety, tolerability and pharmacokinetics/
pharmacodynamics in patients with Muckle-Wells
syndrome (CAPS patients)
Three-part trial (only parts I and II were used for pharmacokinetic/
pharmacodynamic analysis)
Part I: 150mg SC (or 2mg/kg for paediatric subjects £40 kg) SD
Part II: patients were assigned to one of the following two treatment arms in
a ratio of 1 :1, 150mg or 2mg/kg (for paediatric subjects £40 kg) SC every
8 weeks or placebo for up to 24 weeks
CAPS= cryopyrin-associated periodic syndromes; IV = intravenous; MD=multiple dose; RA= rheumatoid arthritis; SC = subcutaneous; SD= single dose.
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anti-idiotype anti-canakinumab antibody coated on micro-
titerplates. Serum samples (calibration, quality control or
unknown samples) and biotin-labelled canakinumab, when
simultaneously incubated, compete for binding to the anti-
idiotype anti-canakinumab antibody. Non-bound material
was removed by washing. Bound biotinylated-canakinumab
was detected by incubating horseradish peroxidase-conjugated
streptavidin followed by washing and incubation with
O-phenylenediamine dihydrochloride as substrate with detec-
tion at 490/650 nm. The intra- and inter-day precision and
accuracy were observed to be below –20% (–25% at LLQ).
Canakinumab is stable in human serum at -20C for at least
12 months.
IL-1b at high concentration levels interferes with the bind-
ing of canakinumab present in the sample or biotinylated ca-
nakinumab used for the quantification to the ELISA plate,
showing that the assay is only able to quantify free canakinu-
mab. However, the highest observed concentration of total
IL-1b during clinical studies (approximately 500 pg/mL or
0.03 nmol/L) was observed with a corresponding canakinumab
concentration of approximately 26 mg/mL (179 nmol/L). In
this most extreme case the percentage of canakinumab bound
to its ligand target represents less than 0.02% of the sys-
temic canakinumab concentration available for binding. The
accuracy and precision of ELISA assays would therefore not
allow differentiation between total canakinumab and free
canakinumab.
3.1.2 Pharmacodynamic Assay
Total IL-1b (free + canakinumab-bound IL-1b) was de-
termined in human serum using a sandwich ELISA method
based on a commercially available kit (Quantikine-HS, R&D
Systems, Minneapolis, MN, USA) with a lower limit of detec-
tion of 0.1 pg/mL. Assay was performed as recommended by
the manufacturer. Presence of canakinumab in the samples
induces a partial inhibition of the IL-1b detection due to the
binding of canakinumab to IL-1b. The observed inhibition was
constant for canakinumab concentrations from 30 ng/mL to
1.2mg/mL. Within this range, the average IL-1b recovery is
75% of the total IL-1b (measured in absence of canakinumab),
with a coefficient of variation (CV) of 5.9%. On the basis of
these results, a correction factor of 1.33 (100/75) was applied to
the determined IL-1b concentration when canakinumab was
present in the sample at concentrations >30 ng/mL. The intra-
and inter-day precision and accuracy were below –20%.
3.1.3 Immunogenicity Assay
A Biacore-based assay was developed and validated ac-
cording to recommendations reported byMire-Sluis et al.[22] to
detect presence of anti-canakinumab antibodies. The principle
of the method is the interaction of anti-canakinumab anti-
bodies with the canakinumab drug and was based on Surface
Plasmon Resonance. The canakinumab drug was immobilized
in a reversible manner to the Biacore sensor chip surface via
protein G, which was covalently bound to the sensor chip.
Subsequently, samples were applied and anti-canakinumab
antibodies were bound to the canakinumab drug. The resulting
response was detected and given as response units. Acid
regeneration after each cycle followed by a new injection of
canakinumab ensured the integrity of the drug. A cycle was
defined as drug injection, sample injection and regeneration.
The sensitivity of this assay was determined to be 0.9 mg/mL
based on a sheep polyclonal anti-canakinumab antibody. The
drug tolerance was determined to be canakinumab 27 mg/mL
based on the sheep polyclonal anti-canakinumab antibody.
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Fig. 1. Serum canakinumab (a) and total interleukin-1b (b) concentration-
time profiles in cryopyrin-associated periodic syndromes patients following
subcutaneous administration of canakinumab 150mg. The data are taken
from study ACZ885A2102 (NCT00487708).[16] IL= interleukin.
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4. Pharmacokinetics and Pharmacodynamics
4.1 Nonclinical Pharmacokinetic Properties
The pharmacokinetics of canakinumab was studied in three
animal species – rhesus monkeys, marmoset monkeys and mice
– and is typical of an IgG-type antibody, with slow serum
clearance and a small volume of distribution at steady state
(Vss). Table II provides a comparison of intravenous pharmaco-
kinetic parameters (calculated by non-compartmental analysis)
in marmoset monkeys, rhesus monkeys, mice and four CAPS
patients. The comparative pharmacokinetic profiles of cana-
kinumab following intravenous administration in these species
are presented in figure 3. The weight-normalized serum clear-
ance of canakinumab derived from the intravenous phar-
macokinetic data reveals a faster clearance in marmoset monkeys
than in other species (0.005, 0.004, 0.003 L/day/kg in mice,
rhesus monkeys and humans, respectively, vs 0.011L/day/kg in
marmosets). It is postulated that the more rapid clearance of
human IgG1 antibodies in the marmoset monkey versus humans
is due to reduced Ig recycling by the FcRn receptor in mar-
mosets.[23] The Vss of canakinumab was 0.0025, 0.26, 0.021 and
7.1 L in mice, rhesus monkeys, marmoset monkeys and hu-
mans, respectively. Accordingly, the half-lives of canakinumab
in these species following intravenous administration of cana-
kinumab were 17.7, 17.4, 4.33 and 31.2 days, respectively. The
bioavailability of canakinumab following single subcutaneous
administration in marmosets was estimated to be 60%, similar
to the bioavailability in humans (60–70%).
4.2 Clinical Pharmacokinetic and Pharmacodynamic
Properties of Canakinumab
Thepharmacokinetics and pharmacodynamics (i.e. total IL-1b)
of canakinumab have been characterized in healthy volunteers
as well as in patients with CAPS, RA, asthma and psoriasis.
Canakinumabwas administered in these studies by intravenous
infusion and/or subcutaneous injections, at a range of doses
under single- and multiple-dose regimens. The pharmacokine-
tics and pharmacodynamics were characterized in the various
studies using extensive and/or sparse sampling. An overview of
the study designs and treatment assignments in each study from
which pharmacokinetic and pharmacodynamic data were
analysed is provided in table I.
For studies that implemented rich sampling, the serum phar-
macokinetic parameters of canakinumab were determined
using non-compartmental analysis (table III). Concentrations
of canakinumab and total IL-1b data from these studies and
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Fig. 2. Mean (and SD) serum canakinumab (a) and total interleukin-1b
(b) concentration-time profiles in healthy Japanese volunteers after a sin-
gle dose of canakinumab. The data are taken from study ACZ885A1101
(NCT00421226).[13] IL= interleukin; IV = intravenous; SC = subcutaneous.
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those with sparse sampling were also analysed using a nonlinear
mixed-effects pharmacokinetic-binding modelling approach
adapted from Lachmann et al.[16] The pharmacokinetic-binding
model integrated both canakinumab and IL-1b inputs and
elimination, plus the binding affinity of canakinumab to IL-1b.
The model also included distribution of canakinumab and
IL-1b between peripheral (‘tissue interstitial’) and central
(‘serum’) compartments.
4.2.1 Pharmacokinetic-Binding Model
Population parameters in the pharmacokinetic-binding
model were estimated using nonlinear mixed-effects model-
ling implemented in NONMEM VI (level 1.2; Icon Develop-
ment Solutions, Ellicott City, MD, USA),[24] using the first-order
estimation method. A description of the pharmacokinetic-
binding model is provided in this section followed by the pre-
sentation of the analysis results.
The Structural Model
A schematic depiction of the pharmacokinetic-binding
model is shown in figure 4. The model contains two physical
compartments, central and peripheral, with three components
in each. The binding of drug (canakinumab) plus target (IL-1b)
to form a complex is assumed to take place in the same physical
space; this was judged physiologically reasonable given both
are hydrophilic proteins and thus constrained to be in the ex-
tracellular fluid. Differential equations have been written based
on the schematic for the amount of canakinumab at the sub-
cutaneous injection site (A), the total drug (canakinumab) in the
serum or central compartment (TDC; measured analyte) and
peripheral compartment (TDP), and the total ligand (IL-1b) in
the serum or central compartment (TLC;measured analyte) and
peripheral compartment (TLP). Free (unbound) species are sim-
ilarly represented by FDC, FDP, FLC and FLP. The bound
Table II. Summary of non-compartmental pharmacokinetic parameters of canakinumab across species (mean– standard deviation)
Parameters Mousea Rhesus monkeyb Marmoset monkeyc Humand
CL (L/day) 0.00010 0.0118– 0.0017 0.00378– 0.0010 0.182–0.0528
CL (L/day/kg)e 0.00494 0.00392–0.00056 0.0108– 0.00288 0.00260– 0.000754
Vss (L) 0.00247 0.262– 0.0744 0.0205– 0.0044 7.08– 2.12
t½ (day) 17.7 17.4–5.24 4.33–0.548 31.2– 3.39
F (%)f NA NA 60 66.5
a CD-1 mice were administered a single dose of IV canakinumab 10mg/kg; serum samples per timepoint were pooled (16 samples per timepoint) to one
aliquot for the ELISA assay, with pharmacokinetic parameters determined from a single profile (Novartis preclinical data).
b Four rhesus monkeys were administered a single dose of IV canakinumab 2mg/kg (Novartis preclinical data).
c Three marmosets were administered a single dose of IV canakinumab 5mg/kg (Novartis preclinical data).
d Four CAPS patients were administered IV canakinumab 10mg/kg in study NCT00487708.[16]
e Serum clearance normalized to a typical body weight of 20 g, 3 kg, 350 g and 70 kg for mouse, rhesusmonkey, marmoset monkey and human, respectively.
f Subcutaneous bioavailability in marmosets was calculated based on Novartis preclinical data where marmosets were administered an SC dose of
canakinumab 5mg/kg; SC bioavailability in humans was calculated from four CAPS patients in study NCT00487708 receiving 10mg/kg IV and 150mg SC
doses of canakinumab on separate occasions.
CAPS= cryopyrin-associated periodic syndromes; CL= serum clearance; F= absolute subcutaneous bioavailability; IV = intravenous; NA= not available;
SC = subcutaneous; t½= terminal elimination half-life; Vss= volume of distribution at steady state.
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1000 Mouse (10 mg/kg IV)
CAPS patient (10 mg/kg IV)
Marmoset (5 mg/kg IV)
Rhesus monkey (2 mg/kg IV)
Fig. 3. Serumconcentration-timeprofiles of canakinumab in adult cryopyrin-
associated periodic syndrome patients, rhesus monkeys, marmoset monkeys
(mean– standard deviation) and mice after a single intravenous administra-
tion of canakinumab. The data are taken from study CACZ885A2102
(NCT00487708)[16] for the cryopyrin-associated periodic syndrome phar-
macokinetic profile, and from animal pharmacokinetic studies (Novartis pre-
clinical data) for marmosets (5mg/kg intravenous), CD-1 mice (10mg/kg in-
travenous) and rhesus monkeys (2mg/kg intravenous). CAPS= cryopyrin-
associated periodic syndromes; IV= intravenous.
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species (the canakinumab-IL-1b complex) is represented by ‘X’,
where XC and XP are the complexes in the central and peri-
pheral compartments, respectively. All species in the equations
are in molar units (i.e. amounts); amounts were then converted
to concentrations by dividing by the appropriate compartment
volume.
The equations are as follows:
Canakinumab absorption from the subcutaneous injection
site (equation 1):
dA=dt¼  ka A (Eq: 1Þ
where ka is the first-order absorption rate constant. Canaki-
numab was also administered as a 2-hour infusion, allowing for
the estimation of the subcutaneous bioavailability.
The total drug (canakinumab) concentration in the serum or
central compartment, TDC (equation 2):
dTDC=dt¼ ka AXC CLX=VC ðTDCXCÞ
 CLD=VCþ ðTDP=VPTDC=VCÞ PSD ðEq: 2Þ
where CLX and CLD are the clearances of the canakinumab-
IL-1b complex and free canakinumab, respectively, which were
Table III. Non-compartmental pharmacokinetic parameters of canakinumab across studies and patient populationsa
Number of
subjects (type)
Dose and route Cmax (mg/mL) tmax (d)
b t½ (d) Vz or Vz/F (L) Vss CL or CL/F (L/day)
Healthy subjects and patients with mild asthma (study CACZ885B2101)[12]
6 (healthy) 1mg/kg IV (day 1, 15) 36.8– 5.78 30.9– 1.50 5.55– 1.42 0.125– 0.0344
6 (healthy) 3mg/kg IV (day 1, 15) 111 –15.3 31.2– 6.44 5.26– 1.16 0.120– 0.0343
5 (healthy) 10mg /kg IV (day 1, 15) 336 –20.2 26.4– 5.70 5.07– 0.990 0.137– 0.0351
20 (asthmatic) 10mg/kg IV (day 1, 15) 395 –79.7 25.7– 3.24 5.64– 1.65 0.156– 0.0643
Japanese healthy subjects (study NCT00421226)[13]
6 (healthy) 1mg/kg IV SD 21– 2.44 22.6– 2.99 5.44–0.921 0.174– 0.0446
6 (healthy) 3mg/kg IV SD 57.5– 5.85 27.4– 5.41 5.65–0.959 0.160– 0.0292
6 (healthy) 600mg IV SD 191–21.2 27.2– 6.61 5.77–0.533 0.168– 0.0239
6 (healthy) 150mg SC SD 16.9– 2.62 5.00 (5.00–9.94) 26.3– 2.02 8.70– 1.34 0.229– 0.0319
6 (healthy) 300mg SC SD 34.1– 6.09 5.00 (2.00–5.00) 26.9– 8.23 8.92– 1.64 0.238– 0.0421
6 (healthy) 600mg IV+ 300mg SC 209–24.9 25.2– 4.00
Patients with active rheumatoid arthritis (study CACZ885A2101 [NCT00619905])[14]
5 (RA) 0.3mg/kg IV (day 1, 15) 8.80– 1.50 19.6– 2.30 7.89– 1.52 0.283– 0.0640
6 (RA) 1mg/kg IV (day 1, 15) 32.2– 8.50 23.7– 8.80 6.35– 0.870 0.203– 0.0680
6 (RA) 3mg/kg IV (day 1, 15) 81.9– 16.2 21.7– 3.0 6.16– 1.30 0.199– 0.0430
20 (RA) 10mg/kg IV (day 1, 15) 329 –62.1 21.2– 5.1 5.87– 1.57 0.200– 0.0660
Patients with psoriasis (study CAZC885A2202 [EudraCT no. 2005-004119-31])[15]
10 (psoriasis) 150mg SC SD 11.9– 4.89 5.00 (2.00–14.0) 26.2– 5.16 15.0– 9.96 0.430– 0.341
CAPS patients with NALP3 mutations (study CACZ885A2102 [NCT00487708])[16]
4 (adult CAPS) 10mg/kg IV SD 149–45.4 31.2– 3.39 8.19– 2.42 7.08–2.12 0.182– 0.0528
25 (adult CAPS) 150mg SC SD 15.9– 3.52 6.98 (1.92–14.0) 26.1– 7.31 8.33– 2.62 0.228– 0.0597
2 (paediatric CAPS) 150mg SC SD 13.4 4.61 (2.16–7.05) 22.9 7.67 0.232
3 (paediatric CAPS) 2mg/kg SC SD 11.2– 3.14 2.00 (2.00–6.96) 24.7c 3.39c 0.0966c
a All values given are for mean– standard deviation, unless otherwise specified.
b Median (range) for single SC dose.
c Data are presented for two subjects as the elimination phase could not be characterized for the third patient.
CAPS= cryopyrin-associated periodic syndromes; CL = total serum clearance estimated from IV data; CL/F = apparent total serum clearance estimated from
SC data; Cmax=maximum (peak) serum concentration; F= absolute SC bioavailability; IV= 2-hour intravenous infusion; RA= rheumatoid arthritis;
SC = subcutaneous; SD= single dose; t½= elimination half-life; tmax = time of peak serum concentration (from SC administration); Vss = volume of distribution
at steady state; Vz = volume of distribution (based on the terminal phase estimated from IV data); Vz/F =apparent volume of distribution (based on the terminal
phase estimated from SC data).
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assumed to be the same; VC and VP are the volumes of distri-
bution of the central (serum) and peripheral compartments,
assumed to be the same for canakinumab, IL-1b and the com-
plex; and PSD is the intercompartmental permeability-surface
area coefficient (distributional clearance) between central and
peripheral compartments for free canakinumab and the complex.
The total drug (canakinumab) concentration in the peri-
pheral compartment, TDP (equation 3):
dTDP=dt¼ ðTDC=VCTDP=VPÞ PSD (Eq: 3Þ
The total IL-1b concentration in the serum or central com-
partment, TLC (equation 4):
dTLC=dt¼ XC CLX=VCFLC CLL=VCþ ðFLP=VPFLC=VCÞ
 PSLþ ðXP=VPXC=VCÞ PSD ðEq: 4Þ
where CLL is the clearance of free IL-1b and PSL is the ex-
change coefficient for the free IL-1b between the central and
peripheral compartments.
The total IL-1b concentration in the peripheral compart-
ment, TLP (equation 5):
dTLP=dt¼RLI=17 000þ ðFLC=VCFLP=VPÞ
 PSLþðXC=VCXP=VPÞ PSD ðEq: 5Þ
where TLP is assumed to gain mass of IL-1b from the en-
dogenous production rate of IL-1b, denoted as RLI, con-
verted from ng/day into nmol/day by the molecular mass of
17000 ng/nmol.
The amount of canakinumab-IL-1b complex was de-
termined by the law of mass action, assuming rapid achieve-
ment of equilibrium binding (quasi-steady-state assumption)
[equation 6]:
KD¼ FD½   FL½ = X½  (Eq: 6Þ
where KD is the equilibrium dissociation constant for binding
of canakinumab to IL-1b. Rearrangement of the previous
equation gives the amount of the canakinumab-IL-1b complex
in the central compartment as a quadratic solution to the








This equation was replicated for the analogous equilibrium
of drug, ligand and complex in the peripheral compartment
(subscript P instead of C). The quantities of canakinumab-IL-
1b complex, XC and XP, were thus available as a function of
total drug, total ligand and the KD for use in equations 2, 4 and
5. Simultaneous fitting of canakinumab and total IL-1b data
therefore enabled the estimation of pharmacokinetic param-
eters as well as the drug-ligand dissociation constant, KD, and
the rates of production and elimination of IL-1b.
The Stochastic Model
The model was run with logarithmically transformed input
concentration data. The residual error was therefore specified
with an additive model and the output equations were loga-
rithmically transformed. The final output of each measured
analyte was given by equation 8:
Yn¼ logðIPREnÞ þ en (Eq: 8Þ
where IPREn was equal to the total amount of drug, TDC, or
ligand, TLC, divided by the central compartment volume, VC,
and n the compartment number; and en corresponded to the
within-subject residual error variance for the respective analyte.
All patient-level parameters (yP,i) in the base model had a typ-
ical value for the population, yP, with a log-normally distributed,
multiplicative patient-level effect, exp(ZP) [equation 9]:
yP;i¼ yP  expðZP;iÞ (Eq: 9Þ
In addition, the absolute bioavailability of the drug from the
subcutaneous injection site was coded using a logit transfor-























Fig. 4. Binding and kinetic model for canakinumab and interleukin-1b. CLD = clearance for drug; CLL= clearance for ligand; CLX= clearance for complex;
IL= interleukin; ka =absorption rate; KD = binding dissociation constant between drug and ligand; PSD = intercompartmental permeability-surface area co-
efficient for drug ; PSL= intercompartmental permeability-surface area coefficient for ligand;RLI = production rate of ligand;VC = central volume;VP= peripheral
volume.
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Covariates to explain inter-subject variability, such as body
weight, age, sex, ethnicity, laboratory values (e.g. albumin
levels), study population (CAPS patients, non-Japanese or
Japanese healthy volunteers, RA, asthma or psoriasis patients)
and cell line change, were evaluated in the model to assess any
differences among the subgroups that might affect canakinu-
mab pharmacokinetics or its binding affinity to IL-1b. Co-
variate relationships and model components (such as random
effects on parameters) were initially assessed based on graphical
exploration of interindividual variance (ZP,i) versus covariates,
pharmacological or physiological plausibility as well as changes
in the objective function. The covariates suggested by the gra-
phical analysis were tested for inclusion in the model. In all
cases, the relationship between parameters and continuous
subject covariates was modelled with a centred power model.
The influence of categorical subject covariates (e.g. patient
type) was modelled as a proportional increase or decrease in the
parameter value. Each potential covariate-parameter pair was
formally tested for insertion into the model with a stepwise
forward inclusion algorithm; all models were tested in parallel
runs, after which the model with the largest drop in the objec-
tive function (at least 3.84 for a single parameter for p < 0.05
significance) was then carried forward. If more than one
covariate-parameter pair was added at the same time, the signif-
icance level was determined from a chi-squared (w2) statistical
table for p £ 0.05 and the appropriate number of degrees of
freedom.
Pharmacokinetic-Binding Modelling Results
The pharmacokinetic-binding model was applied to the
pharmacokinetics and total IL-1b concentration data from
the six clinical studies in table I (n = 233 subjects). This model
successfully fitted the canakinumab and total IL-1b concen-
tration-time data (figure 5), allowing estimation of canakinu-
mab pharmacokinetics and the dynamics of its binding to IL-1b
in CAPS patients, other patient populations and healthy vo-
lunteers. The successful convergence and fit of the model in-
dicated that the assumptions of pseudo-equilibrium, shared
volumes of distribution and complex clearance equivalent to
drug clearance were reasonable. Plots of the weighted residuals
versus time from all six studies are individually presented and
were well centred with relatively few outliers and little tendency
to drift over time (figure 6).
The final model parameters are summarized in table IV. The
parameters for a typical 70 kg CAPS patient with the median
values of serum albumin of 43 g/L and age 34 years were esti-
mated as follows: CLD 0.174 – 0.0124L/day; VC 3.30 – 0.135;
and VP 2.71 – 0.151 L. Subcutaneous bioavailability ranged
from 63% to 70% for the two cell lines. Canakinumab binding
to IL-1bwas reflected in the KD value of 1.1 – 0.2 nmol/L in the
CAPS population. CLL was 14.2 – 2.55L/day and RLI was
9.57 – 1.34 ng/day. Interindividual variability was moderate for
clearance and volume (24–29% CV), and greater for the ab-
sorption rate (64% CV) and the IL-1b binding and turnover
(input-output) parameters (51–63% CV). Canakinumab clear-
ance and IL-1b production were well estimated with little
shrinkage to the mean (4.6% and 10%, respectively), reflecting
good sampling design for these parameters. The less easy to
estimate parameters were IL-1b clearance and the permeability-
surface area coefficient, each of which exhibited moderate
shrinkage (36% and 45% for PSD and PSL, respectively, and
27% for CLL). Residual error shrinkage was low (7.6% and 10%),
indicating that the two-compartment model was a good approx-
imation of canakinumab and IL-1b disposition.
Covariates for the pharmacokinetic parameters were body
weight, population type, and serum albumin levels on CLD,
body weight on VC and VP, and age on the subcutaneous ka.
Covariates for the IL-1b-related parameters were population
type on IL-1bRLI and KD, and population type on IL-1b CLL.
The relationship between parameters and subject covariates are
provided in table IV and discussed in section 4.2.2 and section 5.
4.2.2 Basic Pharmacokinetic Properties of Canakinumab
Absorption
As shown in figure 1, following a single (initial) subcuta-
neous canakinumab 150mg administration in CAPS patients,
canakinumab was slowly absorbed from the injection site
reaching a maximum serum concentration (Cmax) of 15.9 –
3.52 mg/mL in approximately 7 days. Accordingly, the ka value
estimated by the pharmacokinetic-binding value was low
(0.3 day-1). The absolute bioavailability of canakinumab derived
from the NS0 cell line was estimated to be 63 – 5%, while that
from the Sp2/0 cell line was 70 – 8% (table IV). The incomplete
bioavailability of canakinumab injected subcutaneously is likely
due to proteolytic degradation within the reticuloendothelial
system following uptake from the tissue interstitial rather than
the blood side as the drug transits the lymphatics to the thoracic
duct. The 63–70% subcutaneous bioavailability of canakinu-
mab is in line with the bioavailability estimates of other IgG
type monoclonal antibodies.[26]
Distribution
The apparent volume of distribution during the terminal
phase computed by noncompartmental analysis following
subcutaneous administration of canakinumab in adult CAPS
patients was low, averaging 8.33 – 2.62L, slightly greater than
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the serum volume and typical for the distribution of large
macromolecules (table III). Based on the pharmacokinetic-
binding model, the total Vss in a typical CAPS patient weighing
70 kg was estimated to be 6.0 L. With a molecular weight of
approximately 150 kDa, the extra-vascular distribution of ca-
nakinumab is expected to be very small.
Elimination
As canakinumab is a human IgG with a large molecular size
(~150 kDa), little intact immunoglobulin can be filtered by the
kidney and therefore not much renal excretion is expected.
Secretion into the bile is not a significant contributor to the
elimination of IgG antibodies. The majority of IgG elimination
occurs via intracellular catabolism, following fluid-phase or
receptor mediated endocytosis.[26]
In line with the pharmacokinetic properties of a typical IgG
antibody, based on non-compartmental analysis, the apparent
serum clearance after subcutaneous administration (CL/F)
averaged 0.228L/day in adult CAPS patients, resulting in a
long elimination half-life (t½) averaging 26.1 days following
single subcutaneous administration of canakinumab (table III).
The serum clearance of canakinumab estimated by the phar-
macokinetic-binding model was 0.174 L/day in a typical CAPS






























































































































Fig 5. Diagnostic plots from the population-based pharmacokinetic-bindingmodel for (a–c) canakinumab and (d–f) interleukin-1b: observed vs individual- and
population-predicted concentrations and NONMEM weighted residuals vs population-predicted concentrations. The line through each plot is a local regression.
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bioavailability of 70%, CL/F of 0.249 L/day agreed closely with
the non-compartmental value.
Dose Proportionality
Canakinumab exhibits dose-proportional pharmacokine-
tics, both when given as an intravenous infusion (0.3–10mg/kg)
and when administered as a single subcutaneous injection
(150–300mg). There were three pharmacokinetic studies (healthy
volunteers and RA patients; table III) in which at least three
dose strengths of canakinumab were tested. In figure 7, dose-
normalized exposure (area under the serum concentration-time
curve [AUC]) values remain fairly constant across the in-
travenous dose range of 0.3–10mg/kg in RA patients, indicat-
ing dose-proportionality.[14] Dose independence of canakinumab
clearance was also demonstrated by plotting the individual
estimates of clearance from the population pharmacokinetic-
binding model against the administered dose (figure 8). The
linear regression slope of this relationship is approximately
zero, indicating that clearance is dose-independent.
Even though the formation of canakinumab-IL-1b com-
plexes had been demonstrated, there was no evidence of target-
mediated drug disposition.Unlike target-mediated elimination,
where clearance decreases as a function of dose, no dose- or
concentration-dependent changes in elimination or exposure
were observed, and the Vss was constant across the dose ranges.
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Fig. 6. Diagnostic plots from the population-based pharmacokinetic-binding model for canakinumab and interleukin-1b: NONMEM weighted residuals
vs time for each study. The study populations are taken from six studies: (a) study CACZ885B2101[12] (healthy subjects and asthmatic patients); (b) study
CACZ885A1101 (NCT00421226)[13] [Japanese healthy subjects]; (c) study CAZC885A2202[15] (psoriasis patients); (d) study CACZ885A2101
(NCT00619905)[14] (rheumatoid arthritis patients); (e) study CACZ885A2102 (NCT00487708)[16] [cryopyrin-associated periodic syndromes; phase II]; and
(f) study CACZ885D2304 (NCT00465985)[11] [cryopyrin-associated periodic syndromes; phase III].
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Table IV. Population pharmacokinetic-binding model estimated parameters
Parameter (units) Population mean
[y –SE of y]
Interindividual variance
[Z –SE of Z (CV)]
Shrinkage (%)
Canakinumab
CLD (L/d at 70 kg and 43g/L albumin)
CAPS 0.174– 0.0124 0.0859–0.0147 (29%) 4.64
Caucasian HV 0.137– 0.00657




VC (L at 70 kg) 3.30–0.135 0.0589–0.0205 (24%) 21.0
VP (L at 70 kg) 2.71–0.151 0.0817–0.0200 (29%) 30.9
PSD (L/d) 0.429– 0.0529 0.280– 0.107 (53%) 36.0
ka (d
-1 for 34 year old)
NS0 cell line 0.299– 0.0382 0.406– 0.107 (64%) 13.8
Sp2/0 cell line 0.269– 0.0634
F1
NS0 cell line 63.3%–5.26%a
Sp2/0 cell line 70.0%–8.25%a
IL-1b
CLL (L/d)














CAPS 1.07–0.173 0.395– 0.130 (63%) 28.8
Caucasian HV 1.01–0.283




PSL (L/d) 0.386– 0.0555 0.254– 0.139 (50%) 45.2
Continued next page
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directed against cell-surface antigens often exhibit nonlinear
pharmacokinetic behaviour while antibodies (such as canaki-
numab) directed against soluble receptors (e.g. soluble IL-1b)
exhibit linear behaviour.[27]
Pharmacokinetics after Repeated Administration
Canakinumab exhibits dose- and time-independent phar-
macokinetics. In five of the six studies listed in table I, multiple
doses of canakinumab were administered, thus allowing for the
assessment of canakinumab pharmacokinetics after repeated
administration; long-term pharmacokinetic and pharmaco-
dynamic assessments were performed in two of the CAPS
trials,[11,16] with some patients exposed to canakinumab treat-
ment for 9 months to over 2 years. There was no evidence of
time-dependent alteration of the pharmacokinetic profile of
canakinumab in any of the studies. Figure 6 shows a plot of the
weighted residuals (the normalized difference between the ob-
served and predicted concentrations from the population
pharmacokinetic-binding model) versus time for canakinumab
and total IL-1b. The pharmacokinetic-binding model includes
an assumption of time-invariance of the pharmacokinetic pa-
rameters; thus, any drift in the residuals in a positive or negative
direction would indicate that this is an invalid assumption. The
residuals were randomly distributed around the zero value and
showed no directional shift in the plot.
The time to steady state was estimated to be approximately
130 days (~5 half-lives), with accumulation of approximately
1.3-fold for a subcutaneous dosing regimen administered every
8 weeks in a typical adult CAPS patient weighing 70 kg.
None of the patients in the two CAPS studies showed a
treatment-induced immune response to canakinumab that can
alter the pharmacokinetic properties of canakinumab.
4.2.3 In Vivo Binding Properties of Canakinumab
IL-1b at baseline prior to initiation of canakinumab treat-
ment could not be detected in themajority of patients, including
CAPS patients. This is in contrast to the detection of total IL-1b
following administration of canakinumab in all groups includ-
ing healthy subjects and patients. The apparent paradox of
not observing elevated IL-1b in the majority of the CAPS
Table IV. Contd
Parameter (units) Population mean
[y –SE of y]
Interindividual variance













Residual error variances [r2–SE (CV)]
Canakinumab 0.0527–0.00572 (23%) 7.58
IL-1b 0.0840–0.0113 (29%) 10.3
a Estimated on the logit scale with mean and SE back-calculated by simulation.
b Exponent for power model on centred covariate.
CAPS= cryopyrin-associated periodic syndromes; CLD = clearance for drug; CLL= clearance for ligand; CV = coefficients of variation; F1= subcutaneous
bioavailability; HV =healthy volunteers; IL= interleukin; ka= absorption rate; KD =binding dissociation constant between drug and ligand; PSD = intercompart-
mental permeability-surface area coefficient for drug; PSL= intercompartmental permeability-surface area coefficients for ligand; RA= rheumatoid arthritis

























Fig. 7. Dose-normalized area under the serum concentration-time curve
following intravenous administration of canakinumab 0.3–10mg/kg vs dose in
rheumatoid arthritis patients. The data are taken from study CACZ885A2101
(NCT00619905).[14] AUC1 =area under the serum concentration-time curve
from time 0 to infinity.
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patients despite the fact that IL-1b is produced in excess may be
explained by:
1. the fact that free IL-1b is rapidly cleared from circula-
tion;[28] and
2. that even a high production rate in tissues may not lead to a
measurable increase in IL-1b levels in serum.
The IL-1b in subjects including CAPS patients is only quan-
tifiable when the clearance of IL-1b is decreased by binding to
the human anti- IL-1b antibody (i.e. canakinumab).
Total IL-1b concentrations increased following canakinu-
mab dosing in patients, including CAPS patients (figure 1)
as well as healthy subjects (figure 2). The population estimate
of the apparent KD for the binding of canakinumab to IL-1b
in CAPS patients was 1.07 – 0.173 nmol/L (table IV). As ex-
pected, this value differed from the in vitro KD value; system-
specific factors such as production and elimination rate of
endogenous IL-1b, a dynamic system with a changing dis-
tribution equilibrium between tissues and blood compartment,
and competition with other IL-1b binding entities such as sol-
uble receptors may explain the differences between the in vivo
and in vitroKD estimates. The estimated population means for
KD were 1.07 nmol/L in adult CAPS patients, 0.543 nmol/L in
adult asthma patients, 0.227 nmol/L in adult RA patients,
0.360 nmol/L in adult psoriasis patients, 1.01 nmol/L in healthy
subjects of mostly Caucasian descent and 0.354 nmol/L in
healthy Japanese volunteers (table IV).
RLI also varied with study population, being greatest in
CAPS patients at 9.57 ng/day. The other study populations had
IL-1b production rates that ranged from 4.5 to 8.06 ng/day.
5. Effect of Demographic Characteristics and
Extrinsic Factors
The effect of various covariates on the pharmacoki-
netic and binding properties of canakinumab was explored
primarily with the population pharmacokinetic-binding model
as well as through comparison of non-compartmental phar-
macokinetic parameters across studies in various patient
populations. A brief summary of the findings are presented in
this section.
5.1 Age and Body Weight
Based on the population model, age (range 4–74 years)
did not impact any key pharmacokinetic parameters (serum
clearance, VC and VP) after correction for body weight. Body
weight is the most significant covariate influencing canakinu-
mab exposure, a phenomenon commonly observed for most
other monoclonal antibodies.[29]
The serum clearance and volumes of canakinumab were
centred on the median body weight of 70 kg in the CAPS
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Fig. 8. Canakinumab serum clearance (estimated by the pharmacokinetic-binding model) vs dose. CL= serum clearance; IV= intravenous; SC= subcutaneous.
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described by an allometric relationship (equation 10):
y¼ y70 kg  ðWT=70Þexp (Eq: 10Þ
where y is the parameter (CLD, VC, VP); and exp is the allo-
metric exponent (0.70, 0.68 and 0.80, respectively). The esti-
mated coefficients for serum clearance and VP were not
significantly different from the general scaling relationships
of 0.75 and 1, respectively,[30-32] although there was a slight
deviation from proportionality for the central volume. The
exponent value of less than 1 for the clearance-body weight
relationship generally signifies a faster rate of clearance in
smaller children than in adults, relative to their body weight.
Additionally, ka appeared to slow with age, with a 1.5-fold
decrease in the rate constant when age doubles.
5.2 Renal Function
As canakinumab is a human IgG immunoglobulin with large
molecular size (~150 kDa), impairment of renal function is not
likely to influence the pharmacokinetics of canakinumab. This
was supported by the (non-compartmental) clearance and Cmax
values of the four CAPS patients with moderate to end-stage
renal insufficiency: CL/F following the initial 150mg sub-
cutaneous dose was 0.230, 0.246, 0.196 and 0.217L/day, similar
to the mean adult CL/F value of 0.228L/day observed in the
phase II clinical study in CAPS patients (table III). Cmax values
were 20.7, 13.3, 11.1 and 11.7mg/mL, also close to themean adult
Cmax value of 15.9mg/mL.
5.3 Sex
Data from 135 males and 98 females were included in the
population pharmacokinetic analysis. No sex-related differ-
ence was apparent in any of the pharmacokinetic or binding
parameters (e.g. serum clearances in male and female subjects
were 0.186 and 0.176L/day, respectively).
5.4 Patient Population
Pharmacokinetic parameters were generally comparable
across the healthy subjects and patient populations. As sum-
marized in table III, the average serum clearance (based on
non-compartmental analysis of each treatment arm) following
intravenous administration ranged from 0.120 to 137, 0.160 to
0.174, 0.200 to 0.283, 0.156 and 0.182 L/day in healthy Cau-
casian subjects, healthy Japanese subjects, RA patients, mild
asthmatics and CAPS patients, respectively; similar values for
clearance were estimated for each population by the phar-
macokinetic-binding model (table IV). The mean for the non-
compartmental estimates of t½ in adult CAPS patients, pso-
riatic patients and in healthy adult Japanese subjects following
a single subcutaneous dose of canakinumab 150mg were 26.1,
26.2 and 26.3 days, respectively. Similarly, the population phar-
macokinetic-binding model results found no clinically relevant
differences in pharmacokinetic properties of canakinumab
between the patient populations.
5.5 Drug-Drug Interactions
No clinical drug interaction studies between canakinumab
and other medicinal products have been performed. The most
common concomitant medications in CAPS patients are
paracetamol, NSAIDs, systemic corticosteroids, antibacterials
(cephalosporin, amoxicillin) and iron supplements. It is not
expected that thesemedications influence the pharmacokinetics
of canakinumab. This is mainly because monoclonal antibodies
are notmetabolized by the cytochrome P450 (CYP) system, and
their mechanism of elimination could be via catabolism, dif-
ferent from metabolic or renal pathways of elimination for small
molecules. In theRApatientswhere canakinumab is administered
along with ongoing methotrexate treatment, the canakinumab
pharmacokinetic parameters did not differ from those collected
from other studies, signifying that canakinumab pharmacokinet-
ics was unaffected when coadministered with methotrexate.
However, there is a theoretical potential for the existence of
less obvious pathways of interaction. Inflammatory disease
states can modulate drug pharmacokinetic properties through
alterations of levels of drug-metabolizing enzymes. Specifically,
the formation of CYP enzymes is suppressed by increased levels
of proinflammatory cytokines (e.g. IL-1, IL-6, tumour necrosis
factor-a) during chronic inflammation.[33-35] Anti-cytokine anti-
bodies that target and neutralize these proinflammatory cytokines
or their receptors are capable of restoration of CYP enzymes to
normal levels.[36] Molecules that bind to IL-1, such as canakinu-
mab, can be expected to indirectly restore the expression of CYP
enzymes to normal levels. Therefore, there is a possibility of drug
interactions with a biologic that reverses an inflammatory con-
dition, thus upregulating levels of CYPs and resulting in increased
clearance of coadministered drugs that are CYP substrates.
5.6 Other Factors
Lower levels of serum albumin correlate with higher serum




Overview of Canakinumab Pharmacokinetics e15
Adis ª 2012 Chakraborty et al., publisher and licensee Springer International Publishing AG. Clin Pharmacokinet 2012; 51 (6)
where the median serum albumin level is 43 g/L. This correla-
tion may be due to the fact that both proteins are rescued from
reticuloendothelial elimination by the Brambell or FcRn re-
ceptor.
6. Biocomparability
During the development of canakinumab a cell line switch
from NS0 to Sp2/0 was implemented. In the early clinical de-
velopment studies, including the first CAPS study,[16] canaki-
numab was derived from an NS0 cell line. Table V summarizes
the supporting pharmacokinetic comparability data addressing
the cell line switch from NS0 to Sp2/0 during canakinumab
development.
Non-clinical pharmacokinetic comparability was demon-
strated between canakinumab derived from the NS0 and Sp2/0
cell lines in a 2-way single-dose (5mg/kg subcutaneous) phar-
macokinetic crossover study in marmosets. The ratio of means
of the pharmacokinetic parameters (AUC and Cmax) of Sp2/0-
derived canakinumabwith reference toNS0-derived canakinumab
ranged from 104% to 107%, suggesting a lack of pharmaco-
kinetic differences in marmosets. Upon successful demon-
stration of non-clinical comparability, the new drug material
derived from the Sp2/0 cell line was introduced in the first phase
III trial in CAPS patients.[11]
A model-based comparison of the two product types in hu-
mans allowed for the estimation of bioavailability of the new
material relative to the previous drug material (table V). Ca-
nakinumab pharmacokinetic parameters were comparable
between the two cell types, in line with the results from the
marmoset bridging study. The relative bioavailability of the
Sp2/0material with reference to theNS0material was 110 – 6%,
indicating comparable bioavailability. In addition, an increase
in total IL-1b was observed irrespective of the drug form used,
indicating capture of the ligand (IL-1b) by canakinumab de-
rived from these two cell lines.
7. Clinical Efficacy of Canakinumab
Canakinumab treatment was effective in achieving a fast,
complete and sustained response (i.e. effective prevention of
disease flare) in adult and paediatric CAPS patients.[16] Acute-
phase serum inflammatory protein markers (CRP and SAA, as
well as serum levels of IL-6 and IL-1 receptor antagonist), white
blood cell counts, neutrophils and platelet counts supported the
clinical observations as they rapidly reached normal levels
following canakinumab injection.
In the same study,[16] relapse of symptoms were shown to be
closely related to serum canakinumab concentrations. A phar-
macokinetic-flare probability model was developed using data
from four CAPS patients with the objective of identifying a
dosing regimen to minimize the probability of flare during ca-
nakinumab treatment.[16] Simulations of various dosing regi-
mens were performed from the final model, and the regimen of
subcutaneous canakinumab 150mg every 8 weeks was selected;
this regimen was predicted to give less than a 1% probability of
relapse once patients were brought to steady-state, and 3%
chance of flare at the end of the first dosing cycle. This regimen
was used in the randomized placebo-controlled study with a total
of 31 patients.[11] Results from the study showed that within a
Table V. Comparability exercises and the canakinumab pharmacokinetic parameters of the pre- and post-change material for the cell line switch
Parameter NS0 Sp2/0
Drug substance concentration ‡52mg/mL ‡65mg/mL, ‡180mg/mL
Drug substance manufacturing scale (approximate working volume) 220L, 1100L 11 000L
Marmoset pharmacokinetic comparability
t½ (days) 7.07– 1.83a 6.33– 1.91a
Cmax (mg/mL) 1.07 (0.90, 1.26)
b
AUClast (mgday/mL) 1.04 (0.90, 1.21)b
AUC1 (mgday/mL) 1.04 (0.91, 1.20)b
Human pharmacokinetic comparabilityc
Relative bioavailability 1.10 (0.996, 1.20)b
a Mean–SD.
b Values are expressed as geometric mean ratio (reference: NS0; test: Sp2/0) [90% CI].
c From the pharmacokinetic-binding model.
AUC1 = area under the serum concentration-time curve from time 0 to infinity; AUClast =area under the serum concentration-time curve from time 0 to the last
measurable concentration sampling time; Cmax =maximum (peak) serum concentration; SD= standard deviation; t½= elimination half-life.
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period of 24 weeks, all patients randomized to canakinumab
remained disease free, whereas 81% of patients on placebo flared,
thus supporting 150mg every 8 weeks as an effective dosing
regimen.
In addition, the long t½ of canakinumab of approximately
4 weeks supports the use of an every 8-week dosing regimen in
CAPS patients. This compares favourably with the shorter t½
of other anti-IL-1b agents, such as anakinra (4–6 hours)[37] and
rilonacept (~1 week).[38] Canakinumab, with dosing only every
8 weeks, thus represents a major step forward in the manage-
ment of CAPS when compared with the currently available
IL-1b-targeted alternate treatments.
8. Safety Assessments of Canakinumab
The overall safety of canakinumab as assessed in completed
and ongoing clinical trials demonstrates a good tolerability
profile, as evidenced by very few discontinuations, few injection
site reactions, a slightly increased rate of non-serious infections
of the upper respiratory tract, and reported events of vertigo in
CAPS patients that were nomore frequent than the rate in prior
medical histories. The safety and tolerability of canakinumab
demonstrated in the two CAPS trials[11,16] were further con-
firmed in a long-term phase III study evaluating the safety and
efficacy of canakinumab in CAPS patients of different severity
phenotypes.[39]
Anti-canakinumab antibodies in serum were measured by sur-
face plasmon resonance spectroscopy using a sensitive and val-
idated Biacore binding assay. None of the subjects treated with
canakinumab in the six different clinical studies developed anti-
canakinumab antibodies, as measured by the Biacore binding
assay, indicating a low-immunogenic potential of canakinumab.
9. Conclusions
Canakinumab has the expected pharmacokinetic properties
typical of human IgG-type immunoglobulins, such as slow
serum clearance and a low Vss. Canakinumab has high absolute
subcutaneous bioavailability (70%) and a long t½ of approxi-
mately 4 weeks. Canakinumab exhibits dose-proportional
and time-independent pharmacokinetics; there is no evidence
of accelerated clearance or time-dependent changes in the
pharmacokinetics following repeated administration. The phar-
macokinetics of canakinumab in various disease states (e.g.
CAPS, RA, psoriasis or asthma) are comparable to those in
healthy individuals. No sex- or age-related pharmacokinetic
differences were observed after correction for a patient’s body
weight.
The ability of canakinumab to capture and thereby reduce
levels of free IL-1b was demonstrated in all clinical studies,
irrespective of the type of population. An increase in total IL-1b
concentrations was observed after canakinumab dosing, in-
dicating the binding of IL-1b by canakinumab; this binding
leads to the blockage of downstream events of IL-1b signalling,
including IL-1b production, IL-1b pathway-related gene acti-
vation, e.g. elevation of acute phase proteins such as SAA and
CRP, and mobilization of neutrophils and platelets from bone
marrow. As a result, canakinumab demonstrates convincing
evidence of efficacy in IL-1b-driven inflammatory diseases such
as CAPS.
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